#1WEGO威高 Investor Presentation FY2022 Results Announcement March 2023 CONSCIENCE | INTEGRITY | LOYALTY The Leading Total Solutions Provider in the PRC Medical Devices Sector#2Contents P2 FY2022 Business Highlights P5 P15 WEGO威高 Strategic Outlook FY2022 Financial Performance 1#3WEGO FY2022 Business Highlights#4Key business highlights of 2022 Robust growth despite the pandemic Despite the challenges posed by the COVID-19, VBP, and stock channeling, WEGO's key products have maintained an upward growth trend in terms of market share, resulting in higher-than-industry revenue growth rate In 2022, revenue was RMB13.62 billion, representing a y-o-y growth of 3.1%; Net profit attributable to owners of the company was RMB2.72 billion, representing a y-o-y growth of 19.7% Kil Sales channel integration Continuous promotion of sales channel integration, redirecting marketing resources to core customer development and retention, improving product penetration of key account as well as average customer value Increased the customer reach to include more county-level hospitals and established more city-level satellite offices, demonstrating the unwavering commitment to providing exceptional customer services to hospitals at all levels New business initiatives Grew various new business segments such as digital clinical care production, life science information and support solutions, urology, endocrinology, endoscopy and rehabilitation related products Digital clinical care products are expected to boom in 2023. In rehabilitation, introduced international leading brain-computer interactive rehabilitation training system WEGO威高 1 • Blood irradiators for civil use Revenue of Rad Source was RMB0.43 billion, representing a y-o-y growth of 29%. Since 2018, Rad Source started developing direct-to-consumer irradiators for irradiation of raw materials, particles and seeds to eliminate pathogens and parasites. With leading technology and global leadership position, the product has significant market potential and a broad range of application areas including high-end traditional Chinese medicines and raw meat & seafood China's leading medical device conglomerate . Fruitful R&D achievements Boosted R&D investment in 2022 with RMB 550mm R&D expenditure in total, marking a y- o-y growth of 9%, continuously iterating existing product portfolio and proactively develop new products. Invested in 4 healthcare funds to participate in startup incubation and to closely track industry trends rth Global development opportunities In 2022, WEGO established new overseas business development based on original strategy, proactively expanded overseas market and explored global clients and partners Overseas business recorded significant growth as its revenue increased by 19.2% on y-o-y basis 3#5Business segment update Medical devices Despite the impact of the pandemic on demand for medical devices, which further adversely affected the sales volume of medical consumables, the Company leveraged the balanced product portfolio, expanded customer base, and controlled to significantly increase the market share 2022 % y-o-y revenue growth Expanded the offerings in specialized fields such as anesthetic respiratory care, urology, endocrinology, endoscopy, rehabilitation and digital products Orthopedic products Seized the opportunity presented by VBP to become the leading provider in the market. With hospitals listing WEGO as the top choice, the Company's market share is set to soar Optimized the sales channels to streamline operation ✰ The impact of VBP has become milder, allowing us to quickly increasing market share and promote innovation Pharma packaging Interventional products ✰ The pre-filled syringe injectors have achieved a y-o-y revenue growth of 9.3%. Excluding the sales of the COVID vaccines, sales volume of the pre-filled syringe injectors has grown by 42% ✰ WEGO will enhance production capacity to capture the market demand, strengthen service capabilities catering to downstream pharmaceutical companies, increase client loyalty to capture the sustained long-term growth of the industry Explore overseas opportunities to increase global market share Excluding the impacts from supply chain challenge, Argon's revenue has achieved about 15% of y-o-y growth Argon's new product registration process and marketing efforts in China have progressed smoothly, resulted in a 23.3% revenue growth from China market % of segment¹ % of revenue profit +5.2% 50.4% 41.5% -13.9% 13.4% 18.4% +3.2% 15.5% 28.6% +11.8% 12.7% 4.7% +12.4% 8.0% 6.8% Blood management WEGO威高 With the support from WEGO, Argon's global supply chain will gradually resume and is projected to return to a growth rate of over 15% As a leading player in the domestic blood collection industry, WEGO will leverage its expertise in blood collection to expand its presence in areas such as blood component collection and blood therapy, while actively pursuing opportunities to enter overseas markets Rad Source has recorded a revenue y-o-y growth of 29%. The direct-to-consumer irradiators have registered a sales of 80 units, and are used for irradiation of raw materials, particles and seeds to eliminate pathogens and parasites. There is a significant potential for expanded application use Note: 1 The calculation of profit breakdown does not include other segment profits of RMB64.02mm. 4#6WEGO Strategic Outlook#7Company strategy ☑ In response to the policy changes, competition landscape, clinical demands and the accumulation of resources, WEGO proposed the three operational strategies - "platform-based”, “international" and "digital" development, and two guarantee strategies - "talents" and "innovation" Platform-based development - unleash the advantages of an open, inclusive, and collaborative platform • Build a diverse product ecosystem and an efficient collaborative organizational structure, achieving greater economies of scale Deliver comprehensive product solutions that exceed customer expectations and expand product lines while perfecting each product to its finest International development - maintain WEGO's leading position domestically and achieve collaborative development across the borders • Through strategic investment and licensing-ins, we bring high-end medical devices and cutting-edge technologies to China • Explore overseas opportunities actively. WEGO hopes to move from being a Chinese exporter to becoming a multinational corporation. The Company's goal is to achieve a globalization rate of over 50% in the next 10 years Digital development - improve management capability to new heights with the digital strategy and explore new opportunities for growth • Continue to improve digital management capabilities, enhance our edge in production, R&D, and marketing operations • Expand the digital product portfolio, such as Mobile Nursery Management Software, and explore new growth opportunities Talents establish a talent incentivization framework - • Attract and cultivate top-tier talents, build a comprehensive talent incentive framework to engage and inspire our employees, to unleash their creativity Innovation - boost innovation capabilities and achieve sustainable growth • Iteration of existing products: to improve functionality, utilize new materials, and lower production costs New products: Established R&D centers in Shanghai and Suzhou, recruiting R&D talents, focusing on tackling key technological challenges and developing major breakthrough products • Via fund investment, to stay ahead of industry trends and invest for the future WEGO威高 6#8Platform-based development sales platform integration Continue to promote sales channel integration, and redirect marketing resources on core customer development and retention. The Company has seen increasing penetration rate among the key clients (especially the tertiary hospitals) Continue to expand into new markets and seize the enormous potential brought by VBP. WEGO rapidly increased the customer outreach to include more county-level hospitals and established more city-level satellite offices, demonstrating the unwavering commitment to providing exceptional customer services to hospitals at all levels Xinjiang Tibet WEGO威高 Number of customers (as of 31 Dec 2022) Heilongjiang Jilin New customers Total number of domestic customers Total number of overseas customers Inner Mongolia Liaoning Hospital 486 3,601 3,595 Beijing Tianjin Hebei Shanxi Ningxia Shandong Qinghai Gansu Shaanxi Henan Jiangsu Blood stations 414 Hubei Sichuan Chongqing Anhui Shanghai Zhejiang Hunan Jiangxi Guizhou Fujian Other medical units 18 1,119 1,683 Taiwan Yunnan Guangdong Guangxi Hainan Distributors 617 3,969 2,076 Headquarter 35 sales branches Total 1,121 9,103 7,354 2,896 sales representatives in 228 cities 7#9Platform-based development new business initiatives Digital clinical care products Trusted by nearly 50 top-tier • tertiary hospitals • . • • Helps the nursing department to enhance standardization and uniformity level of patient care services, reducing workload of medical staff, lowering personnel costs and enhancing job welfare Error-free drug administration so far, preventing the occurrence of adverse events With the pilot period of fast accumulation of customer base, the installation base is expected to experience explosive growth by 2023 Generate synergies to boost the sales of the clinical consumable products • • Life science information and support solutions Leveraged the expertise of the sales lead who has MNC experiences, to build a high- performing sales team The product portfolio consists of the monitoring equipment, infusion pumps, ventilators, and digital management systems Achieved 2,000 installations across various clinical departments in the first year of the team, including anesthesia, ICU, emergency, respiratory and rehabilitation Suzhou R&D center has recruited a state-of-the-art R&D team, with first product expected to be available for commercialization by 2024, bringing in also synergies with consumables sales . Urology Stents: leveraging the latest international metal stent technology, WEGO has set up China sales office, and has initiated effort to locally develop the product, which is set to commercialized in 2 years Medical energy-based equipment: targeting on the innovative solutions including thulium lasers and pulsed thulium lasers. Currently WEGO has entered an initial phase, with plan to explore the full potential of thulium laser technology in respiratory, digestive, head and neck surgery and medical aesthetics areas Actively engaging in dialogues with MNCs to explore partnership opportunities . • • Endocrinology Developed a team in 2022 The product portfolio includes glucose meters, glucose test strips, and insulin syringes, etc. Currently in process to introduce an overseas CGM product with superior technology compared to the competitors, expected to be launched in 2024 To create a in-and-ex-hospital chronic disease management system, for real time communication between physicians and patients, to ensure continuous care on disease progress. Patients are able to obtain health data in real time, to achieve an integrated information management system WEGO威高 8#10Platform-based development new business initiatives (cont') 40 Endoscopy Rehabilitation Safe automatic drug administration system • • Leveraging partnership with external experts and integration with external team, WEGO incorporated the cutting-edge technologies and achieved breakthroughs in core technology development In 2024, the Company is expecting to launch, amongst others, disposable ureteroscopes, cystoscopes, endoscopes, 4K image processing systems The products set to launch in 2025 include disposable bronchoscopes, hysteroscopes, 4K/8K fluorescence endoscopes and related supporting products, confocal endoscopes, narrow-band imaging products and respiratory iterative products • There is enormous potential for growth in the demand for rehabilitation medical services with supports from the government By 2022, WEGO has entered the market centered around precision rehabilitation. WEGO introduced a brain-machine interface rehabilitation training system, which has qualified as the first medical device registration certificate in China and has been the first device enrolled into the promotion list for key medical equipment by Ministry of Industry and Information Technology Highly recognized by multiple national authorities and they have added "brain- machine interface rehabilitation training" to procurement catalogs as an innovative technology Introduced various intelligent and digitized products including joint rehabilitation robots for sports rehabilitation treatment, cognitive impairment rehabilitation assessment and training system • Developed various drug administration system products including automatic injection pens, disposable multi-dose injection pens, repeatable pen-style injectors, and electronic intelligent pens Committing to enhance patient safety for family medicine and to improve compliance with WEGO's product solutions WEGO威高 9#11International development Connecting China to the globe, building stronger WEGO business by global collaboration WEGO has integrated the internal resources and established an overseas business unit, to continuously drive the international development process. By leveraging the global resources, the Company integrated R&D, production, sales and distribution, and services to enhance WEGO's industry competitiveness and to promote the upgrading and refinement of the entire industry vertical Despite the challenges posed by the global economic downturn in 2022, the overseas business has remained stable and experienced significant growth. Its revenue from overseas has increased by 19.2% yoy Strategic goal of WEGO's global expansion plan: 1. Domestic market: WEGO is committed to bringing high-end medical device products and advanced technologies to the Chinese market through strategic investments and licensing-in to improve the product structure and optimize the product portfolio 2. Overseas market: over the next decade, WEGO is dedicated to achieving parity with international industry leaders, accelerating the Company's global expansion plan, transforming from an original equipment manufacturer to a brand manufacturer. WEGO hopes to move from being a Chinese exporter to becoming a multinational corporation. The Company's ultimate goal is to achieve globalization rate of over 50% WEGO North America center 2022 WEGO感高 WEGO WEGO Europe center WEGO 2023 South America center 2023 WEGO Overseas Business Department (Shanghai) 2023 Southeast Asia Regional Center (Singapore) 2022 10 10#12Digitalization development 1 Digitalized production and operation WEGO leverages the power of digital development to improve operational efficiency, reduces production costs, and enhances product quality, ultimately boosting the manufacturing competitiveness Internet of Things (IoT) technology IoT enables seamless connectivity between products, production equipment and personnel, optimizing the manufacturing process, tracking entire production process in real-time, and enabling the staff to quickly identify any issues that may arise Al-assisted QC technology Al technology helps the Company streamline quality control, reducing testing time, minimizing the risk of errors and personnel costs and improving product quality rate • 2 Digitalized products WEGO has established a hospital-centric information infrastructure system, offering integrated and intelligent total information solutions The digital clinical products enhance the automation level of clinical nursing work in hospitals WEGO has developed a service platform for nurses, creating an online community platform for the clinical care Mobile Nursing System Nursing Management System Mobile Doctor Ward Round System WEGO感高 11#13Innovation and talents strategies WEGO thrives to accelerate future development embracing new opportunities, pushing boundaries of innovation, expanding in-house R&D investment, and gathering top talents Iteration of existing product offerings Improving the existing products and investing in further R&D in line with the product line strategy Upgrading the existing products to improve functionality, utilizing new materials, and lowering production costs Boosting R&D investment In 2022, the Company has invested RMB 550mm in R&D, posting an increase of 9% compared to the previous year. Meantime, WEGO's R&D team has continued to expand In 2022, the Company obtained 123 new patents, had 171 patents under application and received 60 new product registration certificates WEGO威高 Innovation strategy Personnel strategy Attracting top talents Attracting top talents from around the world, including senior executives from multinational corporations The sub-headquarter in Shanghai offers a strategic location that enables the Company to bring together more talents The talented team not only supports the development of the exiting business segments, but also enables the Company to explore new business opportunities and revenue streams Strategic planning for new products Established R&D centers in Shanghai and Suzhou, focusing on tackling key technological challenges and developing major breakthrough products Aim to expand the product portfolio through domestic and international M&As, driving innovation and bringing new solutions to the market, including infusion port products, integrated sports medicine solutions, and precision medical products Investing in potential new ventures WEGO is committed to staying ahead of industry trends, proactively making strategic investments and acquisitions to drive growth and expand the business In recent years, the Company has invested in four domestic and international healthcare focused funds with a total size of RMB 3.3bn, tapping into a diverse range of fields including medical aesthetics, orthopedics, robotics, rehabilitation, and medical materials 12#14ESG Sustainable green development Environment management: stay committed to the principles of green development. With a robust and comprehensive environmental management system in place, WEGO adheres strictly to all relevant environmental protection laws and regulations in the areas where the company operates Energy conservation and low-carbon practices: actively support the global initiatives to combat climate change. Starting from October 2022, WEGO strategically entered the hospital energy management business. The goal is to help institutions implement an intelligent energy system to save energy consumption and reduce CO2 emission. In doing so, WEGO is expected to also create new business growth opportunities Resource and emissions management: starting from the origin to optimize resource utilization and reduce pollution emissions. WEGO invests in environmental technology to improve production processes and set annual targets for resource utilization and emissions reduction Social and community investment • Corporate social responsibility: take concrete actions to give back to society through various charitable donations and social welfare activities. WEGO has contributions in supporting local education and medical research, helping to cultivate talented professionals in these fields Employee development: WEGO is committed to creating a non-discriminatory, equal, harmonious, and safe working environment for all employees Opportunities for people in need: WEGO's subsidiary Jierui is the largest social welfare enterprise in Shandong province, providing employment for nearly a thousand individuals with disabilities and helping them bond with society 000 Responsible business operation Improve governance: strictly adheres to the Governance Principles for Listed Companies in Appendix 14 of the Listing Rules Build sustainable supply chain: seeks partners who share WEGO's high standards of business ethics. By strengthening the supplier management practices, WEGO works together with the partners to promote mutual growth Anti-corruption: WEGO's zero-tolerance policy towards corruption, bribery and extortion reinforces the commitment to uphold its business ethics. All employees are required to sign the "WEGO's Ten Commitments" to demonstrate their dedication to anti-corruption and promoting integrity WEGO威高 Picture: Lake landscape formed from industrial wastewater after waste processing 13#15Core competitiveness Corporate culture, reputation and impact Always follow the corporate culture of conscience, integrity and loyalty to meet clinical needs There is strong demand in the market for our products. The implementation of volume-based procurement has facilitated the efficiency improvement along the industry chain of medical equipment and consumables, which is greatly beneficial for the Company in boosting market share 83 Open and inclusive platform . Promote the synergy and resource sharing between segments, stimulating flexibility and vitality of each sector to the fullest Actively cultivate and develop new business segments, which may become new growth drivers D China's leading medical device conglomerate Customer and distribution channel resources Create an outstanding marketing system adaptive to domestic market, improving channel advantages through continuous channel integration Continue to diversify product portfolio through R&D, cooperation with global parties, M&A, and aim to fully utilize the channel advantages Solid Manufacturing Foundation Notable advantage in automation, material science, cost control, capacity, quality control, etc., and eligible for volume-based procurement in terms or requirement on both price and quality Continue to enhance the digital development in manufacturing, and actively strengthen foothold in new materials and technologies to maintain and enhance the competitiveness of manufacturing 312 E WEGO威高 14 1#16WEGO威高 Spring has come, so has the Season of Hope 15#17WEGO FY2022 Financial Performance#18Key financials Revenue 3 (RMBmm) Growth (%) 17.7% 10,364 8,809 2018 2019 9.5% 2018-2022 CAGR: 11.5% 11,345 2020 EBITDA 1,2,3,5 (RMBmm) EBITDA margin(%) 31.5% 31.3% 29.3% Operating profit 1,3,4 (RMBmm) Operating profit margin (%) 15.9% 3.6% 18.0% 19.9% 19.9% 21.8% 23.0% 13,152 13,619 2021 2022 30.8% 30.7% 2018-2022 CAGR: 10.8% 4,051 4,183 3,247 3,322 2,773 2018-2022 CAGR: 18.5% 2,866 3,128 2,066 2,255 1,586 2018 2019 2020 2021 2022 Net profit attributable to owners of the Company 1,2,3,5 (RMBmm) Net margin (%) 18.7% 19.4% 19.0% 19.8% 21.5% 2018-2022 CAGR: 14.7% 2,743 2,408 1,923 2,030 1,587 2018 2019 2021 2022 2018 2019 2020 2021 2022 2 2020 Notes: 1 After deduction of special items such as inventory appreciation due to the acquisition of Argon Medical in 2018 and the one-time transaction fee of the acquisition; After deduction of special item of the one-time debt replacement fee of Argon Medical in 2019; 3 Not including the impact of accounting restatement of business under the same control in 2019, 2020 and 2021; 4 Operating profit refers to the total pre-tax profit of each segment; 5 After deduction of accrual litigation expense in 2021 as well as the deduction of dilution of Group's interest in WEGO Blood Purification, after-tax income recorded from land and housing recycled by government and after-tax expense for WEGO product liability claims in 2022. The above figures are only for the purpose of reflecting the trend at the operational level of the Company. The specific figures are subject to performance reports. 17#19Revenue and profit breakdown (by business segment) Revenue breakdown 2022 Profit breakdown 2022 % of revenue ■Medical device 50.4% ■ Medical device % of profit¹ 41.5% ■ Orthopedic Interventional 13.4% ■ Orthopedic 18.4% 12.7% ■Interventional 4.7% Pharma packaging 15.5% Pharma packaging 28.6% Blood management 8.0% Blood management 6.8% Revenue by business segment (RMBmm) Profit by business segment (RMBmm) 2022 20213 2022 20213 Medical device product 6,859 6,464 Medical device product 1,298 927 Orthopedic products 1,830 2,127 Orthopedic products 576 762 Interventional products 1,726 1,544 Interventional products 147 151 Pharma packaging products 2,105 2,040 Pharma packaging products 896 855 Blood management 1,098 977 Blood management 211 170 Total 13,619 13,152 Total 3,1942 2,9402 WEGO威高 Note: 1 The calculation of profit breakdown does not include other segment profits of RMB64.02mm; 2 The total includes other segment profits of RMB64.02mm (2022) and RMB74.58mm (2021), which are not listed separately; 3 Not including the impact of accounting restatement of business under the same control in 2021. The above figures are only for the purpose of reflecting the trend at the operational level of the Company. The specific figures are subject to performance reports. 18#20Geographic presence of the business Geographic presence Sales from overseas operations was RMB3, 170mm, accounting for 23% of revenue 2022 % of revenue ■ China 76.8% ■ US 9.3% ■ Asia 6.8% ■ EMEA 4.1% ■ Others 3.0% 2021 % of revenue ■ China 79.8% - US 8.7% ■ Asia 5.3% ■ EMEA 3.8% ■ Others 2.4% Revenue by category (RMB mm) 2022 20211 y-o-y growth (%) China US Asia 10,454 10,495 -0.4% 1,272 1,146 11.0% 931 701 32.7% EMEA Others Total 563 502 12.2% 399 308 29.9% 13,619 13,152 3.6% WEGO performance reports. Note: 1 Not including the impact of accounting restatement of business under the same control in 2021. The above figures are only for the purpose of reflecting the trend at the operational level of the Company. The specific figures are subject to 19#21Cash flow and CAPEX Cash flows and CAPEX Affected by the COVID pandemic in 2022, account receivable days of the hospital was slightly extended, while the Company's operating cash flow and free cash flow slightly decreased on a y-o-y basis The Company has recorded positive free cash flow for the fifth consecutive year since 2018 as operating cash flow grew and CAPEX stabilized Cash flows and CAPEX (RMBmm) 4,000 3,000 2,000 1,053 1,053 1,000 806 720 711 432 1,267 3,035 2,697 2,678 2,219 2,321 1,964 1,801 1 1,608 1,424 1,379 0 (40) (78) (213) (294) (246) (621) (1,000) (751) (795) (1,019) (1,014) (942) (896) (1,131) (1,071) (1,070) (1,513) (2,000) 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ■CAPEX WEGO威高 ■Operating cash flow(RMBmm) ■Free cash flow (RMBmm) Note: 1 After deduction of one-time cash outflow 460 RMBmm for product litigation in 2022;2 Not including the impact of accounting restatement of business under the same control during 2012-2021. The above figures are only for the purpose of reflecting the trend at the operational level of the Company. The specific figures are subject to performance reports. 20 20#22Other financial data Other financial data 2022 20213 Inventory turnover in days1 113 101 Account receivable turnover 138 132 Working capital in days1 Account payable turnover in 84 76 days1 Cash and bank balances (RMBbn) Cash and debt Total debt (RMBbn) 6.86 6.63 4.36 4.06 Net cash (Net debt) (RMBbn) Total debt/EBITDA (x) Leverage analysis Net debt/EBITDA (x) Interest coverage ratio² (x) Current ratio Current ratio and return analysis ROE ROA WEGO感高 2.50 2.57 1.0x 1.0x Net cash Net cash 21.9x 3.0x 13.4% 9.2% 28.9x 3.2x 12.9% 8.9% 3 Note: 1 Average working capital days; 2 Interest coverage ratio = EBITDA/financing costs; ³ Not including the impact of accounting restatement of business under the same control in 2021; 3 Not including the impact of accounting restatement of business under the same control in 2021; 4 After deduction of accrual litigation expense in 2021 as well as the deduction of dilution of Group's interest in WEGO Blood Purification, after-tax income recorded from land and housing recycled by government and after-tax expense for product liability claims in 2022. The above figures are only for the purpose of reflecting the trend at the operational level of the Company. The actual figures are subject to performance reports 21#23Development plan Development strategy Benefited from the continuous expansion of global healthcare industry, WEGO plans to boost future development by establishing a platform company and providing systematic solutions. Strategic acquisition Replicating the success of Argon and Rad Source by strategically explore acquisition opportunities to broaden our product portfolio and global market coverage and further increase our scale 06 Strategic acquisition Product diversification and upgrades 05 $ $ WEGO感高 Direct marketing channels Establishing direct sales channels for select product lines in order to provide Weigao with greater pricing power and in turn, higher margins Direct marketing channels Product cooperation . • Partnering with key customers to • ⚫ design bespoke products to better suit client needs WEGO威高 04 01 • Product diversification and upgrading Focus future developments on higher technology and higher margin products where barriers to entry are greater Continuing to diversify our product mix to better combat the evolving market Import substitution 02 Import substitution • Tapping into the high-tech markets • Importing cutting edge technology to meet the growing demands of Chinese consumers Product cooperation Strategic cooperation 03 Strategic cooperation Adopt open and diverse cooperation to • introduce external capital and expertise ⚫ to foster further innovation 22#24Key milestones • • NIKKISO WEGO switched from the GEM to the Main Board in HK Formed a JV with Nikkiso in terms of hemodialysis machine . Won the second prize of the National Technology Invention Award for the new technology of infusion medical consumables preparation and its large-scale application A ARGON MEDICAL DEVICES Announced the acquisition of Argon Medical, a leading U.S. manufacturer of interventional instruments BEST MANAGED COMPANIES 「民全卓越管理公司 Selected as one of China's leading private companies with outstanding management for 4 consecutive years RAD SOURCE • Completed the acquisition of Rad Source, a leading manufacturer of blood irradiators Acquired a controlling interest in a U.S. supplier to enter the Latin American market WEGO威高 Established WEGO Group focusing on disposable medical consumables • Established the orthopedic business Launched dialyzers to enter the hemodialysis market 1988 2004 2005 2007 . 2009 2012 2015 2008 2010 2013 2017 2018 2020 2022 2019 2021 Listed on Signed an 8-year. HKEX'S GEM loan agreement HKEX 香港交易所 with IFC, totaling US$20mm Received the Outstanding Contribution Award for Industry- University-Research Cooperation and Innovation in Shandong Province Formed a JV with Terumo in the field of peritoneal dialysis TERUMO Obtained a 5- year loan of RMB600mm from IFC • Obtained The Company's shares successfully obtained and completed the pilot full circulation in Hong Kong market and became a constituent stock of Hang Seng HK Stock Connect Index RMB1bn IFC green bonds and RMB500 million loan WEGO Orthopedics went public on the STAR Market Established WEGO overseas business department to promote company's international development process WEGO威高 XX 23#25WEGO's corporate structure 2.06% Equity incentive 45.94% Weigao Holdings 52.00% Public WEGO威高 WEGO (Stock code: HK-1066) 100% Medical Device 72.21% WEGO Orthopaedic 89.8% Argon Medical (U.S.) 95.9% Puri Packaging 100% Blood Technology 26.6% Blood Purification • • Biopsy • Blood bags, blood transfusion Dialyzer Clinical care • Wound management Medical testing • Anesthesia and . surgery Infection protection WEGO (Spine & Trauma) • Star Joint • Yahua (Spine & Joint) Bangde (Trauma) • Mingde (orthopaedical materials) • Vascular . intervention Drainage instruments Guidewires & accessories Coating (OEM) • Pre-filled syringes (with injection needles) Pre-filled syringe ancillary products (booster, cone head, screw soft cap, packaging method, etc.) • Dialysis machine equipment • Peritoneal dialysis • Blood irradiators solution • Peritoneal dialysis Small animal irradiators Cell irradiators for research Virus irradiator • related equipment Dialysis centers WEGO威高 Note: 1 including direct shareholding and indirect shareholding. Data as of Dec 31, 2022 24 24#26Disclaimer This document does not constitute, or form part of any offer for subscription or sale of, or solicitation of any offer to subscribe for or sale of any securities of Shandong WEGO Group Medical Polymer Company Limited ("WEGO Group"), nor shall it be construed as calculated to invite any such offer, nor shall it form the basis of, nor can it be relied on in connection with, or act as an inducement to enter into any contract or commitment whatsoever. Forward-Looking Statements This presentation contains certain forward-looking statements with respect to the financial condition, results of operations and business of WEGO Group, and certain of the plans and objective of the management of WEGO Group. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results or performance of WEGO Group to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such forward-looking statements were based on assumptions regarding WEGO Group's present and future business strategies and the political and economic environment in which WEGO Group and its subsidiaries will operate in the future. Reliance should not be placed on these forward-looking statements, which reflect the view of WEGO Group's management as of the date of this presentation only. Confidentiality This document is given to you on a confidential basis and must not be passed to, or their contents disclosed to, any other person and no copy shall be taken hereof. WEGO威高 25 25